Alpha-fetoprotein Predicts the Treatment Efficacy of Immune Checkpoint Inhibitors for Gastric Cancer Patients

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2024 Feb 26

PMID 38408930

Authors

Jingjing Zhang

Lei Wang

Shasha Zhang

Ruijie Cao

Yufei Zhao

Yue Zhao

Yanrong Song

Zhanjun Guo

Affiliations

Soon will be listed here.

Abstract

Background: Immune checkpoint inhibitors (ICIs) are commonly used in conjunction with chemotherapy to improve treatment outcomes for patients with gastric cancer. Since AFP could influence immunity by both inhibiting natural killer (NK) cells and regulating negatively the function of dendritic cells, we evaluated the influence of baseline serum alpha-fetoprotein (AFP) levels on the curative effect of ICIs in advanced gastric cancer (AGC) patients.

Methods: A retrospective analysis was conducted on 158 AGC patients who underwent ICI treatment. The patients were divided into high and low groups based on the AFP threshold of 20 ng/ml. The efficacy of ICI treatment was assessed using objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).

Results: The higher levels of baseline AFP were found to be associated with a decrease in the effectiveness of ICIs, as evidenced by a DCR of 50.0% in the group with high AFP levels compared to 87.7% in the group with low AFP levels (P < 0.001). Further analysis using Kaplan-Meier survival techniques indicated that a high AFP level was linked to shorter progression-free survival (PFS) (P < 0.001) and overall survival (OS) (P = 0.001) in AGC individuals receiving ICIs. After propensity score matching, a log rank test revealed that the high AFP group had a decrease in median PFS (P = 0.011) and median OS (P = 0.036) compared to the low AFP group. The high AFP levels also showed its association with shorter PFS and OS in the subgroup analysis of ICI plus chemotherapy patients.

Conclusions: Baseline AFP levels may predict immune checkpoint inhibitor treatment efficacy in AGC patients.

Citing Articles

PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial.

Wang Y, Lu J, Chong X, Wang C, Chen X, Peng Z Signal Transduct Target Ther. 2025; 10(1):100.

PMID: 40082418 PMC: 11906745. DOI: 10.1038/s41392-025-02193-z.

Beyond the WHO 2020 Classification of Female Genital Tumors: Types of Endometrial Cancer: A Pathological and Molecular Focus on Challenging Rare Variants.

Santoro A, Angelico G, Travaglino A, Inzani F, Arciuolo D, dAmati A Int J Mol Sci. 2024; 25(19).

PMID: 39408649 PMC: 11477420. DOI: 10.3390/ijms251910320.

Machine learning-based cell death marker for predicting prognosis and identifying tumor immune microenvironment in prostate cancer.

Gao F, Huang Y, Yang M, He L, Yu Q, Cai Y Heliyon. 2024; 10(18):e37554.

PMID: 39309810 PMC: 11414577. DOI: 10.1016/j.heliyon.2024.e37554.

References

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Matsueda K, Yamamoto H, Yoshida Y, Notohara K . Hepatoid carcinoma of the pancreas producing protein induced by vitamin K absence or antagonist II (PIVKA-II) and alpha-fetoprotein (AFP). J Gastroenterol. 2006; 41(10):1011-9. DOI: 10.1007/s00535-006-1889-8. View

Suryatenggara J, Wibowo H, Atmodjo W, Mathew G . Characterization of alpha-fetoprotein effects on dendritic cell and its function as effector immune response activator. J Hepatocell Carcinoma. 2017; 4:139-151. PMC: 5713682. DOI: 10.2147/JHC.S139070. View

Liu H, Xu Y, Xiang J, Long L, Green S, Yang Z . Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer. Clin Cancer Res. 2016; 23(2):478-488. DOI: 10.1158/1078-0432.CCR-16-1203. View

BERGSTRAND C, CZAR B . Demonstration of a new protein fraction in serum from the human fetus. Scand J Clin Lab Invest. 1956; 8(2):174. DOI: 10.3109/00365515609049266. View

Wang B, Xie Y, Zheng L, Zheng X, Gao J, Liu X . Both the serum AFP test and AFP/GPC3/SALL4 immunohistochemistry are beneficial for predicting the prognosis of gastric adenocarcinoma. BMC Gastroenterol. 2021; 21(1):408. PMC: 8555135. DOI: 10.1186/s12876-021-01986-0. View

Cao W, Chen Y, Han W, Yuan J, Xie W, Liu K . Potentiality of α-fetoprotein (AFP) and soluble intercellular adhesion molecule-1 (sICAM-1) in prognosis prediction and immunotherapy response for patients with hepatocellular carcinoma. Bioengineered. 2021; 12(2):9435-9451. PMC: 8809995. DOI: 10.1080/21655979.2021.1990195. View

Yau T, Kang Y, Kim T, El-Khoueiry A, Santoro A, Sangro B . Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol. 2020; 6(11):e204564. PMC: 7530824. DOI: 10.1001/jamaoncol.2020.4564. View

Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N . Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol. 2014; 26(1):141-148. DOI: 10.1093/annonc/mdu472. View

10.

Yang X, Chen L, Liang Y, Si R, Jiang Z, Ma B . Knockdown of alpha-fetoprotein expression inhibits HepG2 cell growth and induces apoptosis. J Cancer Res Ther. 2018; 14(Supplement):S634-S643. DOI: 10.4103/0973-1482.180681. View

11.

Le D, Durham J, Smith K, Wang H, Bartlett B, Aulakh L . Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017; 357(6349):409-413. PMC: 5576142. DOI: 10.1126/science.aan6733. View

12.

Munson P, Adamik J, Butterfield L . Immunomodulatory impact of α-fetoprotein. Trends Immunol. 2022; 43(6):438-448. DOI: 10.1016/j.it.2022.04.001. View

13.

Vujanovic L, Stahl E, Pardee A, Geller D, Tsung A, Watkins S . Tumor-Derived α-Fetoprotein Directly Drives Human Natural Killer-Cell Activation and Subsequent Cell Death. Cancer Immunol Res. 2017; 5(6):493-502. DOI: 10.1158/2326-6066.CIR-16-0216. View

14.

Li C, Song B, Santos P, Butterfield L . Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells. Cell Immunol. 2018; 335:59-67. PMC: 6368446. DOI: 10.1016/j.cellimm.2018.10.011. View

15.

Mizejewski G . Does alpha-fetoprotein contribute to the mortality and morbidity of human hepatocellular carcinoma? A commentary. J Hepatocell Carcinoma. 2016; 3:37-40. PMC: 5036612. DOI: 10.2147/JHC.S114198. View

16.

Kawazoe A, Fukuoka S, Nakamura Y, Kuboki Y, Wakabayashi M, Nomura S . Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020; 21(8):1057-1065. DOI: 10.1016/S1470-2045(20)30271-0. View

17.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

18.

Santoni M, Piva F, Conti A, Santoni A, Cimadamore A, Scarpelli M . Re: Gut Microbiome Influences Efficacy of PD-1-based Immunotherapy Against Epithelial Tumors. Eur Urol. 2018; 74(4):521-522. DOI: 10.1016/j.eururo.2018.05.033. View

19.

Li N, Bai C, Zhang R, Ma L, Ren X, Zhang J . Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer. Transl Oncol. 2020; 14(2):101004. PMC: 7777135. DOI: 10.1016/j.tranon.2020.101004. View

20.

Chen D, Lin X, Zhang C, An G, Li Z, Dong B . Activated Wnt signaling promotes growth and progression of AFP-producing gastric cancer in preclinical models. Cancer Manag Res. 2019; 11:1349-1362. PMC: 6376882. DOI: 10.2147/CMAR.S187219. View